ArticlePloS one2026
Family history of diabetes and glycemic progression: A propensity score-based analysis using health checkup data.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFamily history of diabetes mellitus (FH_ DM) is a well-established risk factor for diabetes, but most studies have focused on disease incidence rather than glycemic changes over time. Understanding how FH_ DM affects the magnitude of change in blood glucose biomarkers before clinical diagnosis can inform earlier intervention strategies and optimize screening intervals.
methodsWe analyzed standardized health checkup data from Korean adults aged 20 years or older with repeated measurements over approximately 2-year (n = 25,647) and 4-year (n = 12,831) intervals. Using propensity score matching (PSM), inverse probability of treatment weighting (IPTW), and doubly robust (DR) estimation, we estimated the average treatment effect of FH_ DM on changes in fasting blood glucose (FBG) and hemoglobin A1c (HbA1c). The analytic cohort included individuals with normoglycemia, prediabetes, and diabetes. Sensitivity analyses using robustness values assessed potential unmeasured confounding.
findingsAfter adjusting for 49 measured confounders, individuals with FH_ DM showed consistently greater glycemic progression than those without FH_ DM across all methods. Over 2 years, HbA1c showed a 0.02% greater increase (95% CI: 0.01-0.03) and FBG showed a 0.3 mg/dL greater increase (95% CI: 0.1-0.6) in the FH_ DM group. Over 4 years, the difference in FBG change was 1.3-1.9 mg/dL. Results remained robust when excluding individuals on diabetes medication and across sensitivity analyses.
conclusionsFamily history of diabetes is independently associated with greater glycemic progression across the normoglycemia-to-diabetes spectrum, even after rigorous adjustment for confounding. These findings support the use of FH_ DM as a practical marker for risk-stratified screening strategies. Individuals with FH_ DM may benefit from more frequent glucose monitoring and earlier preventive interventions to delay or prevent diabetes onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.